Cronos Group Inc. (TSX:CRON)
Canada · Delayed Price · Currency is CAD | Market Cap | 1.42B +32.9% |
| Revenue (ttm) | 222.69M +24.6% |
| Net Income | -2.54M |
| EPS | -0.01 |
| Shares Out | 373.66M |
| PE Ratio | n/a |
| Forward PE | 30.17 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 94,248 |
| Open | 3.800 |
| Previous Close | 3.810 |
| Day's Range | 3.760 - 3.820 |
| 52-Week Range | 2.540 - 4.660 |
| Beta | 1.23 |
| Analysts | Buy |
| Price Target | 4.68 (+23.48%) |
| Earnings Date | Aug 10, 2026 |
About Cronos Group
Cronos Group Inc., a cannabinoid company, engages in the cultivation, production, distribution, and marketing of cannabis products in Canada, Israel, and internationally. It offers dried flowers, pre-rolls, oils, vaporizers, edibles, and tinctures under the Spinach, Lord Jones, Lit, and Peace Naturals brand names. The company is headquartered in Stayner, Canada. [Read more]
Full Company ProfileNews
Top Canadian Marijuana Stock Choices For Better Investing In 2026
Many marijuana stock investors have a strong positive outlook on the future of the market. If you've been watching the cannabis sector, then you know how volatile and uncertain trading can be. Yet the...
Cronos Group price target raised to C$5.50 from C$4.50 at TD Securities
TD Securities raised the firm’s price target on Cronos Group (CRON) to C$5.50 from C$4.50 and keeps a Buy rating on the shares.
Cronos Group Inc. (CRON) Reports Record Revenue and Market Growth in Q1 2026
Cronos Group Inc. (CRON) Reports Record Revenue and Market Growth in Q1 2026
Cronos Group (CRON) Q1 2026: EPS $0.04 Beats ($0.01 est), Revenue $45.2M Tops ($44. ...
Cronos Group (CRON) Q1 2026: EPS $0.04 Beats ($0.01 est), Revenue $45.2M Tops ($44.73M est) -- Still 20.0% Undervalued? GF Score 87/100
Cronos Group reports Q1 EPS 4c vs. 2c last year
Reports Q1 revenue $45.21M vs. $32.26M last year. “Cronos delivered record net revenue and gross profit in the first quarter, as we continue to execute against our borderless products strategy…
Cronos Group Q1 Earnings Call Highlights
Cronos Group NASDAQ: CRON reported record first-quarter 2026 net revenue and gross profit, with management pointing to growth in Israel, gains for its Spinach brand in Canada and continued internation...
Cronos Group (CRON) Reports Strong Earnings and Strategic Expansion Plans
Cronos Group (CRON) Reports Strong Earnings and Strategic Expansion Plans
Cronos Group (CRON) Reports Strong Q1 Earnings, Beats Expectations
Cronos Group (CRON) Reports Strong Q1 Earnings, Beats Expectations
Cronos Group Releases Q1 2026 Financial Results
Cronos Group Inc. (CRON) reported Q1 2026 diluted net income per share earnings of $0.04 per share, matching the $0.00 consensus estimate. The post Cronos Group Releases Q1 2026 Financial Results firs...
Cronos Group Earnings Call Transcript: Q1 2026
Record Q1 net revenue and gross profit driven by strong Canadian and international growth, with Spinach leading in vapes and edibles. Pending CanAdelaar acquisition will expand the European footprint, and a renewed share repurchase program reflects confidence in long-term value.
Cronos Group Quarterly report: Q1 2026
Cronos Group has published its Q1 2026 quarterly earnings report on May 11, 2026.
Cronos Group Earnings release: Q1 2026
Cronos Group released its Q1 2026 earnings on May 11, 2026, summarizing the period's financial results.
Cronos Group Inc Q1 Profit Advances
(RTTNews) - Cronos Group Inc (CRON) released earnings for its first quarter that Increased, from last year
Cronos Group Reports 2026 First Quarter Results
Net revenue in Q1 2026 increased by 40% year-over-year to $45.2 million Achieved record net revenue and gross profit in Q1 2026 Reached #1 market share in vapes in Canada 1 Ninth consecutive quarter ...
Cronos Group (CRON) Set to Release Q1 Earnings with Positive Revenue Expectations
Cronos Group (CRON) Set to Release Q1 Earnings with Positive Revenue Expectations
Top Canadian Cannabis Penny Stocks to Watch This Month
The cannabis sector continues to attract investors seeking growth opportunities in 2026. Marijuana penny stocks remain volatile. However, they also offer strong upside potential when market momentum i...
Cronos Expands Pre-Roll Portfolio with Spinach STIX®
TORONTO, May 06, 2026 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos”), an innovative global cannabis company, announced today that Spinach STIX®, its latest innovation in i...
Cronos Group Inc. to Hold Virtual 2026 Annual Meeting of Shareholders
TORONTO, April 29, 2026 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”) will hold its 2026 Annual Meeting of Shareholders on Thursday, June 18, 2026, at 11...
'GIANT STEP FORWARD': Reclassification of medical cannabis lauded
Trulieve founder and CEO Kim Rivers discusses the impact of Trump's administration reclassifying state-licensed medical cannabis from Schedule 1 to Schedule 3 on 'Varney & Co.' 00:00 Introduction & Re...
Cronos Group Proxy statement: Proxy filing
Cronos Group filed a proxy statement on April 24, 2026, providing details for shareholder voting and corporate governance matters.
Cronos Group Proxy statement: Proxy filing
Cronos Group filed a proxy statement on April 24, 2026, providing details for shareholder voting and corporate governance matters.
Cronos Group (CRON) Sees Decline After Initial Surge on Marijuana Rescheduling News
Cronos Group (CRON) Sees Decline After Initial Surge on Marijuana Rescheduling News
'Big Business Opportunity': Cannabis CEO Celebrates DOJ Easing Regulations On Medical Marijuana
The Trump administration reclassified medical marijuana as a less dangerous drug on Thursday. FDA-approved and state-licensed medical marijuana was rescheduled from a Schedule I drug to the less stric...
The cannabis rescheduling is causing celebration — and confusion — as marijuana stocks sell off
Marijuana stocks sold off Thursday, after acting U.S. Attorney General Todd Blanche signed an order rescheduling Food and Drug Administration-approved and state-licensed medical cannabis products as a...
Cannabis rescheduling fuels optimism across industry
The U.S. Department of Justice is immediately loosening restrictions on some marijuana products and accelerating the process of reclassifying the drug as less dangerous in one of the biggest changes t...